论文部分内容阅读
目的探讨乳腺癌特异基因(BCSG1)在乳腺癌新辅助化疗疗效评估中的价值。方法采用免疫组化S-P法和荧光定量PCR方法检测36例乳腺癌患者新辅助化疗(CEF方案)前后乳腺癌组织BCSG1的表达,比较化疗前后肿瘤体积的变化情况,分析新辅助化疗前后BCSG1蛋白表达与肿瘤形态学变化的关系。结果36例乳腺癌患者新辅助化疗后肿瘤体积均有明显缩小(P<0.01),病灶缓解率(CR+PR)为85.6%;新辅助化疗后BCSG1 mRNA表达水平亦明显低于化疗前(P<0.05),BCSG1蛋白高表达率低于新辅助化疗前(P<0.01)。结论乳腺癌新辅助化疗后BCSG1在分子和蛋白水平表达均明显降低,与新辅助化疗后疗效呈负相关(r=-0.539,P<0.01),提示BCSG1可作为乳腺癌新辅助化疗疗效的预测因子。
Objective To investigate the value of breast cancer specific gene (BCSG1) in evaluating the efficacy of neoadjuvant chemotherapy in breast cancer. Methods The expression of BCSG1 in breast cancer tissues before and after neoadjuvant chemotherapy (CEF) was detected by immunohistochemical SP method and fluorescent quantitative PCR method. The changes of tumor volume before and after chemotherapy were compared. The expression of BCSG1 protein was analyzed before and after neoadjuvant chemotherapy And tumor morphological changes. Results The tumor volume of neoadjuvant chemotherapy in 36 patients with breast cancer was significantly reduced (P <0.01) and the CR + PR was 85.6%. The expression of BCSG1 mRNA in neoadjuvant chemotherapy was also significantly lower than that before chemotherapy (P <0.05). The high expression rate of BCSG1 protein was lower than that before neoadjuvant chemotherapy (P <0.01). Conclusions The expression of BCSG1 in breast cancer after neoadjuvant chemotherapy is significantly lower than that in neoadjuvant chemotherapy (r = -0.539, P <0.01), suggesting that BCSG1 may be used as a prediction for the efficacy of neoadjuvant chemotherapy in breast cancer factor.